Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting
15th December 2015 - 5:51 pm
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a summary of the Investigators Meeting which was held in Paris on 11th/12th December. The key objective of the event was to bring together key specialists in the field of Lupus who will be actively involved as clinical investigators in ImmuPharma’s Phase III Lupuzor™ pivotal trial and to brief them about the protocol and the complicated but required procedures to assess efficacy in the Lupus trial.
The event was jointly organised by ImmuPharma and Simbec-Orion, the Company’s contract research organisation conducting the study. The meeting was attended by over 70 investigators and senior coordinators from the USA and Europe who will be involved in this pivotal Phase III trial for Lupuzor™.
The meeting was introduced by ImmuPharma’s Fanny Valleix, Head of Clinical Research in charge of the study and Dr Robert Zimmer, President and Chief Scientific Officer. Dr Daniel Wallace, Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles, a member of ImmuPharma’s Scientific Advisory Board and a Principal Investigator for Lupuzor™’s Phase III trial also presented. His presentation was entitled “The evolution of drug discovery in Lupus: Current status and future directions”. Prof Sylviane Muller, the inventor of Lupuzor™ and Research Director at the CNRS (the French national center for scientific research) presented Lupuzor’s origins, its unique mechanism of action with supportive data of the compound’s strong safety and efficacy profile.
A summary video of the event including interviews with Prof Sylviane Muller, key ImmuPharma, Simbec-Orion and Principal Investigator personel is available on the Company’s website: www.immupharma.co.uk/interviews
Commenting on the event, Tim McCarthy, Chairman, said: “This auspicious event brought together some of the most important specialists and investigators in the field of Lupus. The enthusiasm which everybody displayed within the meeting was truly overwhelming and demonstrates how important this Lupuzor™ trial is to so many people who are involved in bringing an effective treatment to Lupus patients around the world. As a further key milestone accomplished and the first US sites now opened for recruitment of Lupus patients, as confirmed on the ClinicalTrials.gov website, we look forward to providing further positive updates on this Lupuzor™ Phase III study as it progresses.”